Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.

Abstract : Baseline prognostic biomarkers stratifying treatment strategies in first-line metastatic colorectal cancer (mCRC) are lacking. Angiopoietin-2 (Ang-2) is proposed as a potential biomarker in several cancers. We therefore decided to establish the additional prognostic value of Ang-2 for overall survival (OS) in patients with first-line mCRC. We enrolled 177 patients treated with a bevacizumab containing chemotherapy in two prospective phase II clinical trials. Patient plasma samples were collected at baseline. ELISAs were used to measure Ang-2. The multivariable Cox model identified increased lactate dehydrogenase [HR, 1.60; 95% confidence interval (CI), 1.04-2.45; P = 0.03] and Ang-2 log-transformation level (HR, 1.59; 95% CI, 1.14-2.21; P = 0.0065) as two significant independent OS prognostic factors. It exhibited good calibration (P = 0.8) and discrimination (C-index: 0.64; 95% CI, 0.58-0.68). Ang-2 parameter inclusion in the GERCOR reference model significantly and strongly improved its discriminative ability because the C-statistic increased significantly from 0.61 to 0.63 (bootstrap mean difference = 0.07; 95% CI, 0.069-0.077). Interestingly, the addition of Ang-2 binary information with a 5 ng/mL cutoff value to the GERCOR model allowed the reclassification of intermediate-risk profile patients (41%) into two subsets of low and high risks. Our study provides robust evidence in favor of baseline Ang-2 prognostic value for OS adding to the conventional factors. Its assessment appears to be useful for the improvement in risk stratification for patients with intermediate-risk profile. Ang-2 ability to predict OS at diagnosis could be of interest in the selection of patients eligible for intermittent or sequential therapeutic strategies dedicated to the optimization of patients' quality of life and chemotherapy cost-effectiveness. Cancer Epidemiol Biomarkers Prev; 24(3); 603-12. ©2015 AACR.
Type de document :
Article dans une revue
Cancer Epidemiology, Biomarkers and Prevention, American Association for Cancer Research, 2015, 24 (3), pp.603-12. 〈10.1158/1055-9965.EPI-14-1059〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01139951
Contributeur : Christine Dupuis <>
Soumis le : mardi 7 avril 2015 - 14:32:45
Dernière modification le : mercredi 21 mars 2018 - 10:54:09
Document(s) archivé(s) le : mardi 18 avril 2017 - 12:34:17

Fichiers

article_CEBP.pdf
Fichiers produits par l'(les) auteur(s)

La politique de l'éditeur de cet article ne nous permet pas de rendre visible le texte intégral immédiatement. Il sera rendu visible le 01/03/2016

  •  Figs 1-3 Cancer Epidemiol Biomarkers Prev.pdf Fichiers produits par l'(les) auteur(s)  - Commentaire : La politique de l'éditeur de cet article ne nous permet pas de rendre visible le texte intégral immédiatement. Il sera rendu visible le 01/03/2016
  •  137610_1_supp_2785095_nglzs4.pdf Fichiers produits par l'(les) auteur(s)  - Commentaire : La politique de l'éditeur de cet article ne nous permet pas de rendre visible le texte intégral immédiatement. Il sera rendu visible le 01/03/2016

Identifiants

Citation

Marine Jary, Dewi Vernerey, Thierry Lecomte, Erion Dobi, François Ghiringhelli, et al.. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.. Cancer Epidemiology, Biomarkers and Prevention, American Association for Cancer Research, 2015, 24 (3), pp.603-12. 〈10.1158/1055-9965.EPI-14-1059〉. 〈inserm-01139951〉

Partager

Métriques

Consultations de la notice

228

Téléchargements de fichiers

126